Study | Dataset | Sample size | Data type | Attribute |
---|---|---|---|---|
Simulation | Simulated cellsa | 5000 cells | scRNA-seq | Cell type |
Simulated patientsa | 600 patients | RNA-seq | Disease status | |
Glioblastoma | Patel et al., 2014 [33] | 532 cells (5 patients) | scRNA-seq (SMART-seq) | None |
TCGA GBM [34] | 111 patients | Microarray | GBM subtype | |
Alzheimer’s disease | AIBS | 47,396 cells (11 patients) | scRNA-seq (SMART-seq) | Brain cell types |
Grubman et al., 2019 [36] | 13,214 cells (12 patients) | snRNA-seq (10x Genomics) | AD and normal brain cell types | |
Mathys et al., 2019 [15] | 5288 cellsb (48 patients) | snRNA-seq (10x Genomics) | AD and normal brain cell types | |
MSBB [35] | 682 samples (221 patients) | RNA-seq | AD diagnosis | |
Multiple myeloma | MMRF [47] | 647 patients | RNA-seq | PFS |
IUSM Chen et al. 2021 [46] | 22,968 cells (4 patients) | scRNA-seq (10x Genomics) | Subtype cluster (Subtype 1-5) | |
Ledergor et al., 2019 [45] | 13,440 cells (35 patients) | scRNA-seq (MARS-seq) | Malignancy (NHIP, MGUS, SMM, MM) | |
Zhan et al., 2006 [44] | 559 patients | Microarray | OS |